Cargando…

CD163 Expression Was Associated with Angiogenesis and Shortened Survival in Patients with Uniformly Treated Classical Hodgkin Lymphoma

BACKGROUND: Recent studies have reported the prognostic value of tissue-associated magrophages (TAMs) in classical Hodgkin lymphoma (cHL). In addition, TAMs are implicated in the tumor angiogenesis. In this study, we examined the prognostic relevance of TAMs in relation to vascular endothelial growt...

Descripción completa

Detalles Bibliográficos
Autores principales:	Koh, Young Wha, Park, Chan-Sik, Yoon, Dok Hyun, Suh, Cheolwon, Huh, Jooryung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3906082/ https://www.ncbi.nlm.nih.gov/pubmed/24489836 http://dx.doi.org/10.1371/journal.pone.0087066

Ejemplares similares

GLUT1 as a Prognostic Factor for Classical Hodgkin’s Lymphoma: Correlation with PD-L1 and PD-L2 Expression
por: Koh, Young Wha, et al.
Publicado: (2017)

EBV-positive diffuse large B-cell lymphoma of the elderly with aberrant expression of CD3 and TIA-1
por: Lee, Miji, et al.
Publicado: (2013)

Intestinal Diffuse Large B-Cell Lymphoma: An Evaluation of Different Staging Systems
por: Hwang, Hee Sang, et al.
Publicado: (2014)

Prognostic value of immunohistochemical algorithms in gastrointestinal diffuse large B-cell lymphoma
por: Hwang, Hee Sang, et al.
Publicado: (2013)

JL1 Antigen Expression on Bone Marrow Lymphoma Cells from Patients With Non-Hodgkin Lymphoma
por: Kim, Min-Sun, et al.
Publicado: (2020)

Cluster Containing More Than 20 CD3-Positive Cells in Bone Marrow Biopsy Is a Candidate Prognostic Indicator in Peripheral T-Cell Lymphoma, Not Otherwise Specified
por: Shim, Hyoeun, et al.
Publicado: (2019)

CD163 versus CD68 in tumor associated macrophages of classical hodgkin lymphoma
por: Harris, Jonathan A, et al.
Publicado: (2012)

CD163 is a predictive biomarker for prognosis of classical Hodgkin's lymphoma in Saudi patients
por: Ahmed, Huda Al Sayed, et al.
Publicado: (2019)

Yttrium-90 ibritumomab tiuxetan plus busulfan, cyclophosphamide, and etoposide (BuCyE) versus BuCyE alone as a conditioning regimen for non-Hodgkin lymphoma
por: Jo, Jae-Cheol, et al.
Publicado: (2012)

Feasibility of abbreviated cycles of immunochemotherapy for completely resected limited-stage CD20+ diffuse large B-cell lymphoma (CISL 12-09)
por: Yoon, Dok Hyun, et al.
Publicado: (2017)

Prognostic Impact of Age at the Time of Diagnosis in Korean Patients with Diffuse Large B-cell Lymphoma in the Rituximab Era: A Single Institution Study
por: Hwang, Hee Sang, et al.
Publicado: (2021)

Upward trend in follicular lymphoma among the Korean population: 10-year experience at a large tertiary institution
por: Kim, Meejeong, et al.
Publicado: (2021)

Primary mediastinal large B-cell lymphoma: a single-center experience in Korea
por: Ahn, Heui June, et al.
Publicado: (2014)

Addition of rituximab to the CHOP regimen has no benefit in patients with primary extranodal diffuse large B-cell lymphoma
por: Jang, Geundoo, et al.
Publicado: (2011)

Clinicopathologic Characteristics of T-cell Non-Hodgkin's Lymphoma: A Single Institution Experience
por: Ko, Ock Bae, et al.
Publicado: (2009)

Diffuse Large B-Cell Lymphoma with Involvement of the Breast and Testis in a Male Patient
por: Choi, Eunji, et al.
Publicado: (2015)

Abbreviated chemotherapy for limited-stage diffuse large B-cell lymphoma after complete resection
por: Jo, Jungmin, et al.
Publicado: (2014)

Clinical characteristics, treatment, and outcome of primary rectal lymphoma: a single center experience of 16 patients
por: Jeong, Jae Ho, et al.
Publicado: (2017)

Occurrence of sarcoidosis after chemotherapy for non-Hodgkin lymphoma
por: Cho, Hyungwoo, et al.
Publicado: (2016)

Treatment of primary testicular diffuse large B cell lymphoma without prophylactic intrathecal chemotherapy: a single center experience
por: Kim, Jeongseok, et al.
Publicado: (2014)

A Case of Primary Adrenal Diffuse Large B-cell Lymphoma Achieving Complete Remission with Rituximab-CHOP Chemotherapy
por: Kim, Kyung Min, et al.
Publicado: (2009)

Primary central nervous system lymphoma: a new prognostic model for patients with diffuse large B-cell histology
por: Ahn, Yongchel, et al.
Publicado: (2017)

Sequential heart and autologous stem cell transplantation for light-chain cardiac amyloidosis
por: Huh, Jin-Young, et al.
Publicado: (2017)

Ruxolitinib shows activity against Hodgkin lymphoma but not primary mediastinal large B-cell lymphoma
por: Kim, Seok Jin, et al.
Publicado: (2019)

Efficacy of Brentuximab Vedotin in Relapsed or Refractory High-CD30–Expressing Non-Hodgkin Lymphomas: Results of a Multicenter, Open-Labeled Phase II Trial
por: Kim, Seok Jin, et al.
Publicado: (2020)

Treatment outcomes of dose-attenuated CHOP chemotherapy in elderly patients with peripheral T cell lymphoma
por: Choi, Eun-Ji, et al.
Publicado: (2017)

Prognostic Significance of Absolute Lymphocyte Count/Absolute Monocyte Count Ratio at Diagnosis in Patients with Multiple Myeloma
por: Shin, Su-Jin, et al.
Publicado: (2013)

Clinical features and outcomes in patients with human immunodeficiency virus-negative, multicentric Castleman's disease: a single medical center experience
por: Seo, Seyoung, et al.
Publicado: (2014)

Relapse pattern and prognostic factors for patients with primary central nervous system lymphoma
por: Kim, Jeong Eun, et al.
Publicado: (2012)

Expression of CD99 in Multiple Myeloma: A Clinicopathologic and Immunohistochemical Study of 170 Cases
por: Shin, Su-Jin, et al.
Publicado: (2014)

A Case of Type II Enteropathy-Associated T-Cell Lymphoma with Epstein-Barr Virus Positivity
por: Song, Min Jeong, et al.
Publicado: (2014)

Serum beta-2 microglobulin in malignant lymphomas: an old but powerful prognostic factor
por: Yoo, Changhoon, et al.
Publicado: (2014)

Relapse pattern and prognostic factors for patients with primary CNS lymphoma
por: Suh, Cheolwon, et al.
Publicado: (2012)

Autologous stem cell transplantation for diffuse large B-cell lymphoma with residual extranodal involvement
por: Ko, Ock Bae, et al.
Publicado: (2008)

Composite follicular lymphoma and classic Hodgkin lymphoma
por: Kim, Han-Na, et al.
Publicado: (2022)

ESHAP Salvage Therapy for Refractory and Relapsed Non-Hodgkin's Lymphoma: A Single Center Experience
por: Park, Sang Hyoung, et al.
Publicado: (2006)

Checkpoint CD47 expression in classical Hodgkin lymphoma
por: Gholiha, Alex Reza, et al.
Publicado: (2022)

Modified Number of Extranodal Involved Sites as a Prognosticator in R-CHOP-Treated Patients with Disseminated Diffuse Large B-Cell Lymphoma
por: Yoo, Changhoon, et al.
Publicado: (2010)

A phase I/II study of bortezomib plus CHOP every 2 weeks (CHOP-14) in patients with advanced-stage diffuse large B-cell lymphomas
por: Kim, Jeong Eun, et al.
Publicado: (2012)

PB2338: BONE MARROW INVOLVEMENT IN KOREAN PATIENTS WITH LYMPHOMAS: A 21-YEAR LARGE SINGLE-CENTER STUDY: Keywords: Lymphoma, Bone marrow involvement
por: Kim, Min-Sun, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2d83tgee4b1pmbbh392rq8tv9o